Cannabis is packed with powerful compounds beyond THC and CBD—discover 10 key cannabinoids and how they impact your ...

This means it can’t bind to its target – cannabinoid receptor 1 (CB1) – in the brain, but can act on cells in the rest of the ...

Agonists of the type 1 cannabinoid receptor (CB1) show promise as alternative analgesics but are still limited by side effects and tolerance. Reporting in Nature, Rangari et al. apply computation ...

MIRA Pharmaceuticals signs letter of intent to acquire SKNY Pharmaceuticals, adding SKNY-1, a preclinical drug for weight ...

Mira Pharmaceuticals is making moves in weight loss and smoking cessation. The biotech is trying to buy Skny Pharmaceuticals ...

Marijuana use appears to increase the risk of cardiovascular disease, warns a new retrospective study of otherwise healthy ...

Heavy alcohol consumption is a leading cause of gastrointestinal diseases, with binge drinking linked to increased intestinal ...

Researchers from Washington University School of Medicine and Stanford University have developed a compound that simulates a ...

Allied Market Research published a report, titled, "Cannabinoid Based Drug Discovery and Development Market by Receptor Target (CB1 Receptor, CB2 Receptor), by End User (Pharmaceutical Companies, ...

IGC Pharma has added HHS in Canada as a new clinical site for its Phase II CALMA trial of IGC-AD1 to treat agitation in ...

In patients with T1D, cannabinoid hyperemesis syndrome and diabetic gastroparesis have similar symptoms but different ...